Cizzle Bio provides a blood-based diagnostic test for early-stage lung cancer detection using the CIZ1B biomarker. This non-invasive assay offers high sensitivity and accuracy, aiming to improve patient outcomes by enabling earlier diagnosis compared to traditional screening methods.
Funding
Funding not disclosed
Founders
Product
Problem
Lung cancer is the leading cause of cancer-related mortality globally, largely due to late-stage diagnoses. Current screening methods, such as CT scans, suffer from high false positive rates and low patient uptake, necessitating more accessible and accurate early detection tools.
Solution
Cizzle Bio offers a blood-based diagnostic test that identifies the CIZ1B biomarker, which is highly associated with early-stage lung cancer. This non-invasive assay provides high sensitivity and accuracy, addressing the limitations of existing screening modalities. By enabling earlier detection, Cizzle Bio aims to significantly improve patient outcomes and reduce lung cancer mortality rates. The company is also developing similar biomarker tests for other cancer types, such as gastric cancer.
Target Audience
The primary target audience includes oncologists, pulmonologists, primary care physicians, and diagnostic laboratories seeking advanced tools for early cancer detection.
Features
- Blood test utilizing the CIZ1B biomarker for early-stage lung cancer detection.
- Demonstrated high sensitivity (95%) in early clinical studies.
- Non-invasive diagnostic approach, reducing patient discomfort and procedural risks.
- Proprietary technology protected by worldwide patents.
- Development of additional biomarker tests for other cancers, including gastric cancer.